Payment overview · 2025
General Payments
$367.14
19 reported records · 13 companies
Healthcare provider profile · identity verified
James W Norys, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FAYETTEVILLE, AR · NPI 1568407666
Verified facts
What the public records show
CMS Open Payments records show James W Norys, MD received $367.14 in general payments during 2025 across 19 reported records.
CSL Behring accounted for 19.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| CSL Behring | Unresolved — no canonical attribution shown | $72.98 | 19.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $70.61 | 19.2% | 3 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $45.25 | 12.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.05 | 7.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.32 | 6.1% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $20.23 | 5.5% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $19.03 | 5.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.09 | 4.4% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.74 | 4.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.66 | 4.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.62 | 4.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.04 | 3.8% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $13.52 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $367.14 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kcentra Normalized: kcentra |
Biological | CSL Behring | $72.98 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $70.61 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $48.11 | 2 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $45.25 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.05 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.05 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.32 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $22.32 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $20.23 | 1 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $19.03 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $14.74 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.62 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.62 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.04 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 82 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
76 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
101 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
101 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
82 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
159 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
49 | 46 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1007 | 268 |
| Amlodipine Besylate | Amlodipine Besylate | 843 | 223 |
| Levothyroxine Sodium | Levothyroxine Sodium | 791 | 202 |
| Omeprazole | Omeprazole | 739 | 203 |
| Losartan Potassium | Losartan Potassium | 643 | 169 |
| Lisinopril | Lisinopril | 530 | 141 |
| Gabapentin | Gabapentin | 512 | 162 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 460 | 90 |
| Metformin Hcl | Metformin Hcl | 457 | 132 |
| Tramadol Hcl | Tramadol Hcl | 318 | 86 |
| Furosemide | Furosemide | 315 | 88 |
| Trazodone Hcl | Trazodone Hcl | 303 | 96 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 284 | 136 |
| Simvastatin | Simvastatin | 263 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 261 | 77 |
| Tamsulosin Hcl | Tamsulosin Hcl | 256 | 68 |
| Bupropion Xl | Bupropion Hcl | 245 | 67 |
| Escitalopram Oxalate | Escitalopram Oxalate | 239 | 70 |
| Zolpidem Tartrate | Zolpidem Tartrate | 237 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 235 | 72 |
| Clonazepam | Clonazepam | 232 | 48 |
| Alprazolam | Alprazolam | 230 | 53 |
| Meloxicam | Meloxicam | 226 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 209 | 57 |
| Fluticasone Propionate | Fluticasone Propionate | 204 | 85 |
| Potassium Chloride | Potassium Chloride | 200 | 52 |
| Lorazepam | Lorazepam | 198 | 41 |
| Atenolol | Atenolol | 197 | 52 |
| Duloxetine Hcl | Duloxetine Hcl | 196 | 59 |
| Celecoxib | Celecoxib | 185 | 62 |
| Metoprolol Tartrate | Metoprolol Tartrate | 177 | 50 |
| Alendronate Sodium | Alendronate Sodium | 171 | 54 |
| Allopurinol | Allopurinol | 162 | 41 |
| Glimepiride | Glimepiride | 161 | 42 |
| Eliquis | Apixaban | 159 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 159 | 43 |
| Mirtazapine | Mirtazapine | 152 | 45 |
| Pregabalin | Pregabalin | 148 | 42 |
| Carvedilol | Carvedilol | 146 | 40 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 146 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 145 | 32 |
| Ondansetron Odt | Ondansetron | 145 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 143 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 133 | 51 |
| Montelukast Sodium | Montelukast Sodium | 133 | 38 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 130 | 37 |
| Sertraline Hcl | Sertraline Hcl | 125 | 29 |
| Ozempic | Semaglutide | 120 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 119 | 17 |
| Diazepam | Diazepam | 116 | 20 |
| Lovastatin | Lovastatin | 116 | 31 |
| Prednisone | Prednisone | 111 | 73 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 108 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 33 |
| Finasteride | Finasteride | 106 | 29 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 106 | 36 |
| Jardiance | Empagliflozin | 101 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 99 | 26 |
| Ventolin Hfa | Albuterol Sulfate | 99 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 98 | 25 |
| Spironolactone | Spironolactone | 96 | 26 |
| Donepezil Hcl | Donepezil Hcl | 95 | 24 |
| Estradiol | Estradiol | 93 | 22 |
| Famotidine | Famotidine | 91 | 34 |
| Warfarin Sodium | Warfarin Sodium | 90 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 84 | 26 |
| Mounjaro | Tirzepatide | 82 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 78 | 16 |
| Synthroid | Levothyroxine Sodium | 76 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 74 | 29 |
| Pioglitazone Hcl | Pioglitazone Hcl | 72 | 18 |
| Chlorthalidone | Chlorthalidone | 71 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 70 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 69 | 19 |
| Clonidine Hcl | Clonidine Hcl | 69 | 13 |
| Xarelto | Rivaroxaban | 67 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 66 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 58 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 58 | 41 |
| Doxepin Hcl | Doxepin Hcl | 57 | 14 |
| Primidone | Primidone | 57 | 14 |
| Baclofen | Baclofen | 55 | 12 |
| Promethazine Hcl | Promethazine Hcl | 55 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 54 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 52 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | 13 |
| Metformin Hcl Er | Metformin Hcl | 51 | 17 |
| Ipratropium Bromide | Ipratropium Bromide | 50 | 22 |
| Azithromycin | Azithromycin | 49 | 39 |
| Fenofibrate | Fenofibrate,micronized | 49 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 49 | 46 |
| Diclofenac Sodium | Diclofenac Sodium | 46 | suppressed |
| Ezetimibe | Ezetimibe | 46 | 14 |
| Methocarbamol | Methocarbamol | 46 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 46 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 45 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 44 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 44 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 35 |
| Temazepam | Temazepam | 43 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 43 | 17 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 42 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 35 |
| Trulicity | Dulaglutide | 42 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | 11 |
| Farxiga | Dapagliflozin Propanediol | 40 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | suppressed |
| Nifedipine Er | Nifedipine | 40 | suppressed |
| Valsartan | Valsartan | 39 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 38 | 16 |
| Buspirone Hcl | Buspirone Hcl | 38 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 38 | suppressed |
| Fluconazole | Fluconazole | 36 | 18 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 36 | suppressed |
| Acyclovir | Acyclovir | 35 | suppressed |
| Irbesartan | Irbesartan | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Torsemide | Torsemide | 34 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 32 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 22 |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 18 |
| Methadone Hcl | Methadone Hcl | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 24 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 19 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | 11 |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | 12 |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Novolog | Insulin Aspart | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 13 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 16 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Nexium | Esomeprazole Magnesium | 12 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $367.14 · 19 records | CSL Behring | ACCRUFER, AIRSUPRA, DUPIXENT, Dexcom G6 Transmitter, Kcentra, MOUNJARO, NURTEC ODT, OFEV, OTEZLA, Prolastin-C Liquid, QULIPTA, REPATHA, Tyvaso, UBRELVY, ULTOMIRIS, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error